Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Clindamycin phosphate and tretinoin

Drug class: Retinoid

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Clindamycin phosphate and tretinoin key facts

Drug class
Retinoid
Used for
ZIANA Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Typical pharmacy cost
$3.62–$4.39 per gram (clindamycin phosphate 1% · tretinoin 0.025%; NADAC)
Latest FDA recall
None listed

Sources: FDA label (May 15, 2026); FDA NDC Directory (November 13, 2026); CMS NADAC (November 11, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Clindamycin phosphate and tretinoin used for?
The FDA-approved label (Ziana, Bausch Health US, LLC, May 15, 2026) says: “ZIANA Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. ZIANA ® Gel is a lincosamide antibiotic and retinoid combination product indicated for the topical treatment of acne vulgaris in patients 12 years or older.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Clindamycin phosphate and tretinoin?
The “Adverse Reactions” section of the FDA label (Ziana, Bausch Health US, LLC, May 15, 2026) begins: “Observed local adverse reactions in patients treated with ZIANA Gel were skin erythema, scaling, itching, burning, and stinging. Other most commonly reported adverse events (≥1% in patients treated with ZIANA Gel) were nasopharyngitis, pharyngolaryngeal pain, dry skin, cough, and sinusitis.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Clindamycin phosphate and tretinoin?
The “Drug Interactions” section of the FDA label (Ziana, Bausch Health US, LLC, May 15, 2026) begins: “• Concomitant use of topical medications with a strong drying effect can increase skin irritation. Use with caution. (7.1) • ZIANA Gel should not be used in combination with erythromycin-containing products because of its clindamycin component.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Clindamycin phosphate and tretinoin have a boxed warning?
No. None of the 5 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Clindamycin phosphate and tretinoin?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Clindamycin phosphate and tretinoin been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Clindamycin phosphate and tretinoin?
5 companies list prescription products of Clindamycin phosphate and tretinoin in the FDA NDC Directory, including Solaris Pharma Corporation, Oceanside Pharmaceuticals and Encube Ethicals, Inc.

What Clindamycin phosphate and tretinoin is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

ZIANA Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. ZIANA ® Gel is a lincosamide antibiotic and retinoid combination product indicated for the topical treatment of acne vulgaris in patients 12 years or older.

— FDA label: Ziana, Bausch Health US, LLC, effective May 15, 2026. Read the full label on DailyMed →

Label quoted: the one for the most common form (gel, topical), Ziana, Bausch Health US, LLC; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 5 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 5 FDA labels for this medicine have a boxed warning.

Clindamycin phosphate and tretinoin side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

Observed local adverse reactions in patients treated with ZIANA Gel were skin erythema, scaling, itching, burning, and stinging. Other most commonly reported adverse events (≥1% in patients treated with ZIANA Gel) were nasopharyngitis, pharyngolaryngeal pain, dry skin, cough, and sinusitis.

Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Studies Experience Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse reactions that appear to be related to drug use for approximating rates. The safety data presented in Table 1 (below) reflects exposure to ZIANA Gel in 1853 patients with acne vulgaris. Patients were 12 years and older and were treated once daily for 12 weeks. Adverse reactions that were reported in ≥1% of patients treated with ZIANA Gel were compared to adverse reactions in patients treated with clindamycin phosphate 1.2% in vehicle gel, tretinoin 0.025% in vehicle gel, and the vehicle gel alone: Table 1: Adverse Reactions Reported in at Least 1% of Patients Treated with ZIANA Gel: 12-Week Studies ZIANA Gel N=1853 N (%) Clindamycin N=1428 N (%) Tretinoin N=846 N (%) Vehicle N=423 N (%) PATIENTS WITH AT LEAST ONE AR 497 (27) 342 (24) 225 (27) 91 (22) Nasopharyngitis 65 (4) 64 (5) 16 (2) 5 (1) Pharyngolaryngeal pain 29 (2) 18 (1) 5 (1) 7 (2) Dry skin 23 (1) 7 (1) 3 (<1) 0 (0) Cough 19 (1) 21 (2) 9 (1) 2 (1) Sinusitis 19 (1) 19 (1) 15 (2) 4 (1) NOTE: Formulations used in all treatment arms were in the ZIANA vehicle gel. Cutaneous safety and tolerance evaluations were conducted at each study visit in all of the clinical trials by assessment of erythema, scaling, itching, burning, and stinging: Table 2: ZIANA Gel-Treated Patients with Local Skin Reactions Local Reaction Baseline N=1835 N (%) End of Treatment N=1614 N (%) Erythema 636 (35) 416 (26) Scaling 237 (13) 280 (17) Itching 189 (10) 70 (4) Burning 38 (2) 56 (4) Stinging 33 (2) 27 (2) At each study visit, application site reactions on a scale of 0 (none), 1 (mild), 2 (moderate), and 3 (severe), and the mean scores were calculated for each of the local skin reactions. In Studies 1 and 2, 1277 subjects enrolled with moderate to severe acne, 854 subjects treated with ZIANA Gel and 423 treated with vehicle. Analysis over the 12-week period demonstrated that cutaneous irritation scores for erythema, scaling, itching, burning, and stinging peaked at 2 weeks of therapy, and were slightly higher for the ZIANA-treated group, decreasing thereafter. One open-label 12-month safety study for ZIANA Gel showed a similar adverse reaction profile as seen in the 12-week studies. Eighteen out of 442 subjects (4%) reported gastrointestinal symptoms.

Table from the label
Local ReactionBaseline N=1835 N (%)End of Treatment N=1614 N (%)
Erythema636 (35)416 (26)
Scaling237 (13)280 (17)
Itching189 (10)70 (4)
Burning38 (2)56 (4)
Stinging33 (2)27 (2)

— FDA label: Ziana, Bausch Health US, LLC, effective May 15, 2026. This is part of the section. Read the full label on DailyMed →

Clindamycin phosphate and tretinoin drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

  • Concomitant use of topical medications with a strong drying effect can increase skin irritation. Use with caution. (7.1)
  • ZIANA Gel should not be used in combination with erythromycin-containing products because of its clindamycin component.
Read more of this section

(7.2) 7.1 Concomitant Topical Medication Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution. When used with ZIANA Gel, there may be increased skin irritation. 7.2 Erythromycin ZIANA Gel should not be used in combination with erythromycin-containing products due to its clindamycin component. In vitro studies have shown antagonism between these two antimicrobials. The clinical significance of this in vitro antagonism is not known. 7.3 Neuromuscular Blocking Agents Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ZIANA Gel should be used with caution in patients receiving such agents.

— FDA label: Ziana, Bausch Health US, LLC, effective May 15, 2026. Read the full label on DailyMed →

Clindamycin phosphate and tretinoin dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

At bedtime, squeeze a pea-sized amount of medication onto one fingertip, dot onto the chin, cheeks, nose, and forehead, then gently rub over the entire face. ZIANA Gel should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes. ZIANA Gel is not for oral, ophthalmic, or intravaginal use.

  • Apply a pea-sized amount to the entire face once daily at bedtime. Do not apply to eyes, mouth, angles of the nose, or mucous membranes.
Read more of this section

(2)

  • ZIANA Gel is not for oral, ophthalmic, or intravaginal use. (2)

— FDA label: Ziana, Bausch Health US, LLC, effective May 15, 2026. Read the full label on DailyMed →

Clindamycin phosphate and tretinoin in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Pregnancy Category C. There are no well-controlled trials in pregnant women treated with ZIANA Gel. ZIANA Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. ZIANA Gel was tested for maternal and developmental toxicity in New Zealand White Rabbits with topical doses of 60, 180 and 600 mg/kg/day.

Read more of this section

ZIANA Gel at 600 mg/kg/day (approximately 12 times the recommended clinical dose assuming 100% absorption and based on body surface area comparison) was considered to be the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity following dermal administration of ZIANA Gel for 2 weeks prior to artificial insemination and continuing until gestation day 18, inclusive. For purposes of comparisons of the animal exposure to human exposure, the recommended clinical dose is defined as 1 g of ZIANA Gel applied daily to a 60 kg person. Clindamycin Teratology (Segment II) studies using clindamycin were performed orally in rats (up to 600 mg/kg/day) and mice (up to 100 mg/kg/day) (583 and 49 times amount of clindamycin in the recommended clinical dose based on body surface area comparison, respectively) or with subcutaneous doses of clindamycin up to 180 mg/kg/day (175 and 88 times the amount of clindamycin in the recommended clinical dose based on body surface area comparison, respectively) revealed no evidence of teratogenicity. Tretinoin In oral Segment III studies in rats with tretinoin, decreased survival of neonates and growth retardation were observed at doses in excess of 2 mg/kg/day (~78 times the recommended clinical dose assuming 100% absorption and based on body surface area comparison). With widespread use of any drug, a small number of birth defect reports associated temporally with the administration of the drug would be expected by chance alone. Thirty cases of temporally associated congenital malformations have been reported during two decades of clinical use of another formulation of topical tretinoin. Although no definite pattern of teratogenicity and no causal association have been established from these cases, five of the reports describe the rare birth defect category, holoprosencephaly (defects associated with incomplete midline development of the forebrain). The significance of these spontaneous reports in terms of risk to the fetus is not known. Dermal tretinoin has been shown to be fetotoxic in rabbits when administered in doses 40 times the recommended human clinical dose based on body surface area comparison. Oral tretinoin has been shown to be fetotoxic in rats when administered in doses 78 times the recommended clinical dose based on body surface area comparison.

— FDA label: Ziana, Bausch Health US, LLC, effective May 15, 2026. Read the full label on DailyMed →

Clindamycin phosphate and tretinoin and breastfeeding

Quoted from the nursing mothers / lactation part of the FDA-approved label.

It is not known whether clindamycin is excreted in human milk following use of ZIANA Gel. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. It is not known whether tretinoin is excreted in human milk.

Read more of this section

Because many drugs are excreted in human milk, caution should be exercised when ZIANA Gel is administered to a nursing woman.

— FDA label: Ziana, Bausch Health US, LLC, effective May 15, 2026. Read the full label on DailyMed →

When Clindamycin phosphate and tretinoin should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

ZIANA Gel is contraindicated in patients with regional enteritis, ulcerative colitis, or history of antibiotic-associated colitis. ZIANA Gel is contraindicated in patients with regional enteritis, ulcerative colitis, or history of antibiotic-associated colitis. (4)

— FDA label: Ziana, Bausch Health US, LLC, effective May 15, 2026. Read the full label on DailyMed →

Forms and how it is given

Dosage formsGel
RouteTopical
Prescription products5 in the FDA NDC Directory
Brand namesZiana

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Clindamycin phosphate and tretinoin, by strength and form
Strength and formGeneric or brandPharmacies pay
clindamycin phosphate 1% · tretinoin 0.025%
gel
Generic $3.62–$4.39 per gram
4 packages, lowest to highest
clindamycin phosphate 1.2% · tretinoin 0.025%
gel
Generic $3.62–$4.39 per gram
2 packages, lowest to highest

NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA050802
ZIANA
BauschNovember 7, 2006 6, latest March 25, 2016
2016: Manufacturing (CMC) · 2016: Manufacturing (CMC) · 2013: Manufacturing (CMC)

Generic approvals (3)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)882548, 882550
SPL set ID of the quoted label78c329f9-f0c9-486d-9e54-0123699fb9e1
FDA labels (SPL)5
FDA applicationsNDA050802, 3 ANDA
Active ingredients (FDA)CLINDAMYCIN / TRETINOIN

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Ziana, Bausch Health US, LLC, effective May 15, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers